Autologous bone marrow stem cell (ABMSC) transplantation has been utilized in clinical practice to treat patients with liver failure, but the therapeutic effect remains to be defined. A meta-analysis is essential to assess clinical advantages of ABMSC transplantation in patients with liver failure. A systematic search of published works [eg, PubMed, Medline, Embase, Chin J Clinicians (Electronic edition), and Science Citation Index] was conducted to compare clinical outcomes of ABMSC transplantation in patients with liver failure. Meta-analytic results were tested by fixed-effects model or random-effects model, dependent on the characteristics of variables. A total of 534 patients from seven studies were included in final meta-analysis. Subsequent to ABMSC transplantation, there was no significant improvement in general symptom and signs such as loss of appetite, fatigue, and ascites. Activities of serum ALT were not significantly decreased with weighted mean difference (WMD) of −19.36 and 95% confidence interval (CI) −57.53 to 18.80 (P=0.32). Postoperative level of albumin (ALB) was expectedly enhanced by stem cell transplantation (WMD 2.97, 95% CI 0.52 to 5.43, P<0.05, I2=84%). Coagulation function was improved as demonstrated by a short prothrombin time (PT) (WMD −1.18, 95% CI −2.32 to −0.03, P<0.05, I2=6%), but was not reflected by prothrombin activity (PTA) (P=0.39). Total bilirubin (TBIL) was drastically diminished after ABMSC therapy (WMD −14.85, 95% CI −20.39 to −9.32, P<0.01, I2=73%). Model for end-stage liver disease (MELD) scores were dramatically reduced (WMD −2.27, 95% CI −3.53 to −1.02, P<0.01, I2=0%). The advantage of ABMSC transplantation could be maintained more than 24 weeks as displayed by time-courses of ALB, TBIL, and MELD score. ABMSC transplantation does provide beneficial effects for patients with liver failure. Therapeutic effects can last for 6 months. However, long-term effects need to be determined.
Get full access to this article
View all access options for this article.
References
1.
BlachierM, LeleuH, Peck-RadosavljevicM, VallaDC and Roudot-ThoravalF. (2013). The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol, 58:593–608.
2.
SarinSK, KumarA, AlmeidaJA, ChawlaYK, FanST, GargH, de SilvaHJ, HamidSS, JalanR, et al. (2009). Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int, 3:269–282.
3.
RoychowdhuryS, McMullenMR, PisanoSG, LiuX and NagyLE. (2013). Absence of receptor interacting protein kinase 3 prevents ethanol-induced liver injury. Hepatology, 57:1773–1783.
4.
DongiovanniP, AnsteeQM and ValentiL. (2013). Genetic predisposition in NAFLD and NASH: Impact on severity of liver disease and response to treatment. Curr Pharm Des, 19:5219–5238.
5.
ShuhM, BohorquezH, LossGEJr. and CohenAJ. (2013). Tumor necrosis factor-alpha: life and death of hepatocytes during liver ischemia/reperfusion injury. Ochsner J, 13:119–130.
6.
Sanz-GarciaC, Ferrer-MayorgaG, González-RodríguezÁ, ValverdeAM, Martín-DuceA, Velasco-MartínJP, RegaderaJ, FernándezM and AlemanyS. (2013). Sterile inflammation in acetaminophen-induced liver injury is mediated by Cot/tpl2. J Bio Chem, 288:15342–15351.
7.
BantelH and Schulze-OsthoffK. (2012). Mechanisms of cell death in acute liver failure. Front Phys, 3:79.
8.
PengL, XieDY, LinBL, LiuJ, ZhuHP, XieC, ZhengYB and GaoZL. (2011). Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology, 54:820–828.
9.
PaiM, ZacharoulisD, MilicevicMN, HelmyS, JiaoLR, LevicarN, TaitP, ScottM, MarleySB, et al. (2008). Autologous infusion of expanded mobilized adult bone marrow-derived CD34+ cells into patients with alcoholic liver cirrhosis. Am J Gastroenterol, 103:1952–1958.
10.
ShiM, ZhangZ, XuR, LinH, FuJ, ZouZ, ZhangA, ShiJ, ChenL, et al. (2012). Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl Med, 1:725–731.
11.
FitzpatrickE, MitryRR and DhawanA. (2009). Human hepatocyte transplantation: state of the art. J Intern Med, 266:339–357.
12.
GargV, GargH, KhanA, TrehanpatiN, KumarA, SharmaBC, SakhujaP and SarinSK. (2012). Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology, 142:505–512.
13.
ChanG, TaqiA, MarottaP, LevstikM, McAlisterV, WallW and QuanD. (2009). Long-term outcomes of emergency liver transplantation for acute liver failure. Liver Transpl, 15:1696–1702.
14.
HoulihanDD and NewsomePN. (2008). Critical review of clinical trials of bone marrow stem cells in liver disease. Gastroenterology, 135:438–450.
15.
DaiLJ, LiHY, GuanLX, RitchieG and ZhouJX. (2009). The therapeutic potential of bone marrow-derived mesenchymal stem cells on hepatic cirrhosis. Stem Cell Res, 2:16–25.
16.
Trebol LopezJ, Georgiev HristovT, Garcia-ArranzM and Garcia-OlmoD. (2011). Stem cell therapy for digestive tract diseases: current state and future perspectives. Stem Cells Dev, 20:1113–1129.
17.
ShiotaG and YasuiT. (2012). Progress in stem cell biology in regenerative medicine for liver disease. Hepatol Res, 42:15–21.
18.
PolsonJ and LeeWM. (2005). AASLD position paper: the management of acute liver failure. Hepatology, 41:1179–1197.
19.
AmerME, El-SayedSZ, El-KheirWA, GabrH, GomaaAA, El-NoomaniN and HegazyM. (2011). Clinical and laboratory evaluation of patients with end-stage liver cell failure injected with bone marrow-derived hepatocyte-like cells. Eur J Gastroenterol Hepatol, 23:936–941.
20.
LyraAC, SoaresMB, da SilvaLF, BragaEL, OliveiraSA, FortesMF, SilvaAG, BrustolimD, GenserB, Dos SantosRR and LyraLG. (2010). Infusion of autologous bone marrow mononuclear cells through hepatic artery results in a short-term improvement of liver function in patients with chronic liver disease: a pilot randomized controlled study. Eur J Gastroenterol Hepatol, 22:33–42.
21.
El-AnsaryM, Abdel-AzizI, MogawerS, Abdel-HamidS, HammamO, TeaemaS and WahdanM. (2011). Phase II trial: undifferentiated versus differentiated autologous mesenchymal stem cells transplantation in Egyptian patients with HCV induced liver cirrhosis. Stem Cell Rev, 8:972–981.
22.
SaitoT, OkumotoK, HagaH, NishiseY, IshiiR, SatoC, WatanabeH, OkadaA, IkedaM, et al. (2011). Potential therapeutic application of intravenous autologous bone marrow infusion in patients with alcoholic liver cirrhosis. Stem Cells Dev, 20:1503–1510.
23.
SunS, YangF, ZhaoW, YanB, ChenC and XuX. (2012). Clinical observation of hepatic stem cell transplantation on liver cirrhosis with refractory ascites by ultrasonic guided percutaneous portal vein puncture. (Zhong hua Lin Chuang Yi Shi Za Zhi) Chin J Clinicians (Electronic edition), 6:3185–3189.
24.
MaoH, JinH, HuangC, TangY and XieY. (2013). Autologous bone marrow mesenchymal tem cell transplantation can improve liver function of patients with decompensated cirrhosis caused by hepatitis B. (Zhong hua Lin Chuang Yi Shi Za Zhi) Chin J Clinicians (Electronic edition), 7:3289–3293.
25.
StuckAE, RubensteinLZ and WielandD. (1998). Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ, 316:469–471.
26.
Am EschJS, SchmelzleM, FürstG, RobsonSC, KriegA, DuhmeC, TustasRY, AlexanderA, KleinHM, et al. (2012). Infusion of CD133+ bone marrow-derived stem cells after selective portal vein embolization enhances functional hepatic reserves after extended right hepatectomy: a retrospective single-center study. Ann Surg, 255:79–85.
27.
KuoTK, HungSP, ChuangCH, ChenCT, ShihYR, FangSC, YangVW and LeeOK. (2008). Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology, 134:2111–2121.
28.
HongZF, HuangXJ, YinZY, ZhaoWX and WangXM. (2009). Immunosuppressive function of bone marrow mesenchymal stem cells on acute rejection of liver allografts in rats. Transplant Proc, 41:403–409.
29.
KimWH, MatsumotoK, BesshoK and NakamuraT. (2005). Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis. Am J Pathol, 166:1017–1028.
30.
NasirGA, MohsinS, KhanM, ShamsS, AliG, KhanSN and RiazuddinS. (2013). Mesenchymal stem cells and Interleukin-6 attenuate liver fibrosis in mice. J Transl Med, 11:78.
31.
SuhYG, KimJK, ByunJS, YiHS, LeeYS, EunHS, KimSY, HanKH, LeeKS, et al. (2012). CD11b(+) Gr1(+) bone marrow cells ameliorate liver fibrosis by producing interleukin-10 in mice. Hepatology, 56:1902–1912.
32.
HardjoM, MiyazakiM, SakaguchiM, MasakaT, IbrahimS, KataokaK and HuhNH. (2009). Suppression of carbon tetrachloride-induced liver fibrosis by transplantation of a clonal mesenchymal stem cell line derived from rat bone marrow. Cell Transplant, 18:89–99.
33.
LiT, ZhuJ, MaK, LiuN, FengK, LiX, WangS and BieP. (2013). Autologous bone marrow-derived mesenchymal stem cell transplantation promotes liver regeneration after portal vein embolization in cirrhotic rats. J Surg Res, 184:1161–1173.
34.
SatoY, ArakiH, KatoJ, NakamuraK, KawanoY, KobuneM, SatoT, MiyanishiK, TakayamaT, et al.Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. Blood, 106:756–763.
35.
WangL, WangX, ChiuJD, van de VenG, GaardeWA and DeleveLD. (2012). Hepatic vascular endothelial growth factor regulates recruitment of rat liver sinusoidal endothelial cell progenitor cells. Gastroenterology, 143:1555–1563.
36.
VassilopoulosG, WangPR and RussellDW. (2003). Transplanted bone marrow regenerates liver by cell fusion. Nature, 422:901–904.
37.
di BonzoLV, FerreroI, CravanzolaC, MareschiK, RustichellD, NovoE, SanavioF, CannitoS, ZamaraE, et al. (2008). Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential. Gut, 57:223–231.
38.
RussoFP, AlisonMR, BiggerBW, AmofahE, FlorouA, AminF, Bou-GhariosG, JefferyR, IredaleJP and ForbesSJ. (2006). The bone marrow functionally contributes to liver fibrosis. Gastroenterology, 130:1807–1821.
39.
WuXZ and ChenD. (2006). Origin of hepatocellular carcinoma: role of stem cells. J Gastroenterol Hepatol, 21:1093–1098.
40.
HeX, TsangTC, PipesBL, AblinRJ and HarrisDT. (2005). A stem cell fusion model of carcinogenesis. J Exp Ther Oncol, 5:101–109.
41.
ZaimM, KaramanS, CetinG and IsikS. (2012). Donor age and long-term culture affect differentiation and proliferation of human bone marrow mesenchymal stem cells. Ann Hematol, 91:1175–1186.
42.
HuangK, ZhouDH, HuangSL and LiangSH. (2005). Age-related biological characteristics of human bone marrow mesenchymal stem cells from different age donors. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 13:1049–1053.
43.
ChoumerianouDM, MartimianakiG, StiakakiE, KalmantiL, KalmantiM and DimitriouH. (2010). Comparative study of stemness characteristics of mesenchymal cells from bone marrow of children and adults. Cytotherapy, 12:881–887.
44.
MohamadnejadM, AlimoghaddamK, Mohyeddin-BonabM, BagheriM, BashtarM, GhanaatiH, BaharvandH, GhavamzadehA and MalekzadehR. (2007). Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iranian Med, 10:459–466.
45.
MohamadnejadM, NamiriM, BagheriM, HashemiSM, GhanaatiH, Zare MehrjardiN, Kazemi AshtianiS, MalekzadehR and BaharvandH. (2007). Phase 1 human trial of autologous bone marrow-hematopoietic stem cell transplantation in patients with decompensated cirrhosis. World J Gastroenterol, 13:3359–3363.
46.
GasbarriniA, RapacciniGL, RutellaS, ZoccoMA, TittotoP, LeoneG, PolaP, GasbarriniG and Di CampliC. (2007). Rescue therapy by portal infusion of autologous stem cells in a case of drug-induced hepatitis. Dig Liver Dis, 39:878–882.
47.
CoutoBG, GoldenbergRC, da FonsecaLM, ThomasJ, GutfilenB, ResendeCM, AzevedoF, MercanteDR, TorresAL, et al. (2011). Bone marrow mononuclear cell therapy for patients with cirrhosis: a Phase 1 study. Liver Int, 31:391–400.
48.
ShiY, SuJ, RobertsAI, ShouP, RabsonAB and RenG. (2012). How mesenchymal stem cells interact with tissue immune responses. Trends Immunol, 33:136–143.
49.
Garcia-OlmoD, HerrerosD, PascualI, PascualJA, Del-ValleE, ZorrillaJ, De-La-QuintanaP, Garcia-ArranzM and PascualM. (2009). Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum, 52:79–86.
50.
GuadalajaraH, HerrerosD, De-La-QuintanaP, TrebolJ, Garcia-ArranzM and Garcia-OlmoD. (2012). Long-term follow-up of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas. Int J Colorectal Dis, 27:595–600.
51.
AminMA, SabryD, RashedLA, ArefWM, el-GhobaryMA, FarhanMS, FouadHA and YoussefYA. (2013). Short-term evaluation of autologous transplantation of bone marrow-derived mesenchymal stem cells in patients with cirrhosis: Egyptian study. Clin Transplant, 27:607–612.
52.
ParkCH, BaeSH, KimHY, KimJK, JungES, ChunHJ, SongMJ, LeeSE, ChoSG, et al. (2013). A pilot study of autologous CD34-depleted bone marrow mononuclear cell transplantation via the hepatic artery in five patients with liver failure. Cytotherapy, 15:1571–1579.
53.
HanY, YanL, HanG, ZhouX, HongL, YinZ, ZhangX, WangS, WangJ, et al. (2008). Controlled trials in hepatitis B virus-related decompensate liver cirrhosis: peripheral blood monocyte transplant versus granulocyte-colony-stimulating factor mobilization therapy. Cytotherapy, 10:390–396.
54.
HanHS, AhnKS, ChoJY, YoonYS, YoonCJ, ParkKU, MinSK, LeeHK and RyuKH. (2014). Autologous stem cell transplantation for expansion of remnant liver volume with extensive hepatectomy. Hepatogastroenterology, 61:156–161.
55.
ZhangZ, LinH, ShiM, XuR, FuJ, LvJ, ChenL, LvS, LiY, et al. (2012). Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. J Gastroenterol Hepatol, 27:112–120.
56.
KimJK, ParkYN, KimJS, ParkMS, PaikYH, SeokJY, ChungYE, KimHO, KimKS, et al. (2010). Autologous bone marrow infusion activates the progenitor cell compartment in patients with advanced liver cirrhosis. Cell Transplant, 19:1237–1246.
57.
KharazihaP, HellströmPM, NoorinayerB, FarzanehF, AghajaniK, JafariF, TelkabadiM, AtashiA, HonardoostM, ZaliMR and SoleimaniM. (2009). Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol, 21:1199–1205.
58.
KhanAA, ParveenN, MahaboobVS, RajendraprasadA, RavindraprakashHR, VenkateswarluJ, RaoSG, NarusuML, KhajaMN, et al. (2008). Safety and efficacy of autologous bone marrow stem cell transplantation through hepatic artery for the treatment of chronic liver failure: a preliminary study. Transplant Proc, 40:1140–1144.
59.
SpahrL, LambertJF, Rubbia-BrandtL, ChalandonY, FrossardJL, GiostraE and HadengueA. (2008). Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial. Hepatology, 48:221–229.
60.
FürstG, Schulte am EschJ, PollLW, HoschSB, FritzLB, KleinM, GodehardtE, KriegA, WeckerB, et al. (2007). Portal vein embolization and autologous CD133+ bone marrow stem cells for liver regeneration: initial experience. Radiology, 243:171–179.
61.
YanL, HanY, WangJ, LiuJ, HongL and FanD. (2007). Peripheral blood monocytes from patients with HBV related decompensated liver cirrhosis can differentiate into functional hepatocytes. Am J Hematol, 82:949–954.
62.
GordonMY, LevicarN, PaiM, BachellierP, DimarakisI, Al-AllafF, M'HamdiH, ThaljiT, WelshJP, et al. (2006). Characterization and clinical application of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. Stem Cells, 24:1822–1830.
63.
TeraiS, IshikawaT, OmoriK, AoyamaK, MarumotoY, UrataY, YokoyamaY, UchidaK, YamasakiT, et al. (2006). Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells, 24:2292–2298.
64.
YannakiE, AnagnostopoulosA, KapetanosD, XagorariA, IordanidisF, BatsisI, KaloyannidisP, AthanasiouE, DourvasG, KitisG and FassasA. (2006). Lasting amelioration in the clinical course of decompensated alcoholic cirrhosis with boost infusions of mobilized peripheral blood stem cells. Exp Hematol, 34:1583–1587.
